CAMP was conducted to evaluate a lab test that identified children with metabolic imbalances that are associated with autism spectrum disorder (ASD). The study consisted of two main parts: behavioral evaluation and a fasting blood sample. We compared the results of the blood test to the behavioral evaluation to identify differences in the metabolism of children who were diagnosed with ASD.

Enrollment in CAMP is now closed—we have reached our goal of enrolling 1,100 children, 18-48 months old. Thank you to all of the families and clinical sites who participated!

Our new test, ASD Panel, would not be possible without the participation of hundreds of families who enrolled at one of our eight clinical sites throughout the United States. We are grateful that you have taken the time and trouble to help us better understand autism spectrum disorder.

We also appreciate the time and commitment of the staff members at each clinical site listed below, from the Principal Investigators to the administrators of the ADOS-2 (Autism Diagnostic Observation Schedule, Second Edition) to the phlebotomists. Your contribution helped us reach our goal of developing this test, which we can now bring to a wider market to help more kids. Thank you!

UC-Davis MIND Institute
David Amaral – Principal Investigator

Nationwide Children’s Hospital
Daniel Coury – Principal Investigator

Massachusetts General Hospital
Lurie Center for Autism
Ann Neumeyer – Principal Investigator

Melmed Center
Raun Melmed – Principal Investigator

Monroe Carell, Jr. Children’s Hospital at Vanderbilt
Kevin Sanders – Former Principal Investigator
Allyson Cundiff – Principal Investigator

Children’s Hospital of Philadelphia (CHOP)
Amanda Bennett-Palladino – Principal Investigator

Arkansas Children’s Research Hospital
Richard Frye – Former Principal Investigator

Cincinnati Children’s Hospital Medical Center
Logan Wink – Principal Investigator

This study was funded by a grant from the National Institutes of Mental Health and investment by the Nancy Lurie Marks Family Foundation.

The manuscript based on this study—Amino Acid Dysregulation in Autism Spectrum Disorder: Potential biomarkers and targets for individual treatment—has been submitted for publication.

(608) 441-8187

504 S. Rosa Rd. Suite 150
Madison, WI 53719

contact@NeuroPointDx.com

FOLLOW US